Skip to main content

A Study to Assess Efficacy and Safety of KarXT for the Treatment of Psychosis Associated With Alzheimer's Disease (ADEPT-1)

Recruiting · Phase 3 · NCT05511363

Conditions: Psychosis Associated With Alzheimer's Disease

At a glance

Research payments reported, 2025
$6.6M
U.S. investigators named
38
Sites paid
39
Planned or actual enrollment
410

About the trial

Sponsor
Karuna Therapeutics, Inc., a Bristol Myers Squibb company
Tested
KarXT (drug), Placebo (drug)
Dates
Started 2022-08-23; completion 2026-10-05
Results posted
Not yet

This is a Phase 3, 38-week, randomized, double-blind, placebo-controlled, multicenter, outpatient study in subjects with psychosis associated with Alzheimer's Disease. The primary objective of the study is to evaluate relapse prevention in subjects with psychosis associated with Alzheimer's Disease treated with KarXT compared to placebo. The secondary objectives of the study are to evaluate the time from randomization to discontinuation for any reason or relapse and safety and tolerability in subjects with psychosis associated with Alzheimer's Disease treated with KarXT compared to placebo.

From ClinicalTrials.gov, last updated 2026-08-17. Full record, eligibility and contacts (opens in a new tab)

Industry funding

E.r. Squibb & Sons, L.l.c. reported $6.6M in research payments for this study in 2025 (42 payments).

Products named: Cobenfy

Research payments usually go to hospitals, universities and research sites to run a study, not to the investigators personally. A payment is not evidence of wrongdoing.

U.S. investigators named on this study

Clinicians the company named as principal investigators in its Open Payments reports.

Sites paid to run it

  • Betancourt Research Services $986,001
  • Las Mercedes Medical Research $903,969
  • San Marcus Research Clinic, Inc $717,038
  • Coral Clinic Research $639,933
  • Ocean Blue Medical Research Center, Incorporated $530,599
  • On Health Research $413,773
  • Coral Research Clinic Corporation $349,168
  • Allied Biomedical Research Institute $335,610
  • K2 Medical Research - Maitland $293,682
  • Future Care Solution, Llc $228,503
  • Premier Clinical Research Institute $221,367
  • South Florida Research Phase I To Iv, Inc $193,245
  • Novel Clinical Research Center, Llc $158,391
  • Floridian Neuroscience Institute $114,710
  • K2 Medical Research $75,993
  • K2 Medical Research - Winter Garden $71,017
  • Envision Trials, Llc $65,141
  • Clinical Trial Network, Llc $60,544
  • United Research Institute Llc $49,155
  • Synergy Clinical Research Llc $47,605
  • Arrow Clinical Trials $30,599
  • Dade Research Center, Llc $23,411
  • Five Towns Neurology, PC $22,219
  • The Ima Group $21,000
  • The Trustees of Columbia University in The City of New York $17,753
  • The Feinstein Institute for Medical Research $11,424
  • Suny Research Foundation State of Buffalo Ny $10,472
  • Lehigh Center for Clinical Research $7,061
  • Sc3 Research Group, Inc $5,500
  • Tilda Irvine - Ppds $5,431
  • Sfm Clinical Research, Llc $4,771
  • $3,950
  • Suncoast Neurosciences Associates $3,852
  • Tilda Research Inc $3,260
  • Global Medical Institutes, Llc $2,356
  • Research Network America Llc $2,350
  • Atlanta Biomedical Clinical Research $1,300
  • Vial Health Technologies Inc $1,200
  • Jdr Dermatology Research $1,200
  • Pacific Neuropsychiatric Specialists $130

Sources: CMS Open Payments research payments (program year 2025) and ClinicalTrials.gov, U.S. National Library of Medicine.